Wall Street Zen lowered shares of Immuneering (NASDAQ:IMRX – Free Report) from a sell rating to a strong sell rating in a research note released on Saturday morning,Wall Street Zen reports.
Several other research analysts also recently issued reports on the company. Needham & Company LLC upped their price objective on Immuneering from $11.00 to $18.00 and gave the company a “buy” rating in a research note on Monday, July 20th. Weiss Ratings reiterated a “sell (d-)” rating on shares of Immuneering in a report on Monday, September 21st. Mizuho set a $11.00 target price on shares of Immuneering in a research report on Thursday, October 29th. Chardan Capital raised shares of Immuneering to a “strong-buy” rating in a report on Monday, August 3rd. Finally, UBS Group set a $14.00 price target on shares of Immuneering in a research report on Thursday, August 6th. One analyst has rated the stock with a Strong Buy rating, four have assigned a Buy rating and one has assigned a Sell rating to the company. Based on data from MarketBeat, the stock has an average rating of “Moderate Buy” and a consensus target price of $15.67.
View Our Latest Stock Report on IMRX
Immuneering Stock Up 9.2%
NASDAQ IMRX opened at $3.68 on Friday. Immuneering has a twelve month low of $3.35 and a twelve month high of $8.48. The company has a market cap of $238.32 million, a price-to-earnings ratio of -3.57 and a beta of 0.49. The business’s fifty day moving average is $4.12 and its 200 day moving average is $4.77.
Immuneering (NASDAQ:IMRX – Get Free Report) last posted its earnings results on Thursday, October 29th. The company reported ($0.37) EPS for the quarter, missing the consensus estimate of ($0.31) by ($0.06). On average, research analysts anticipate that Immuneering will post -1.19 earnings per share for the current fiscal year.
Hedge Funds Weigh In On Immuneering
A number of hedge funds have recently made changes to their positions in the stock. Integrated Wealth Concepts LLC bought a new position in shares of Immuneering in the 2nd quarter worth about $34,000. Levin Capital Strategies L.P. bought a new stake in shares of Immuneering during the 1st quarter valued at about $53,000. VestGen Advisors LLC boosted its position in shares of Immuneering by 100.0% during the 3rd quarter. VestGen Advisors LLC now owns 20,002 shares of the company’s stock valued at $82,000 after purchasing an additional 10,002 shares in the last quarter. Focus Financial Network Inc. bought a new stake in shares of Immuneering during the 2nd quarter valued at about $62,000. Finally, Principle Wealth Partners LLC bought a new stake in shares of Immuneering during the 3rd quarter valued at about $51,000. 67.65% of the stock is currently owned by institutional investors.
Immuneering Company Profile
Immuneering Corporation is a clinical-stage biopharmaceutical company focused on developing medicines for cancer and other serious diseases. The company uses computational biology and drug-discovery technologies to identify therapeutic opportunities in complex biological pathways, with a particular emphasis on the RAS–RAF–MEK–ERK signaling pathway, which is frequently altered in cancer.
Immuneering’s lead product candidate, IMM-1-104, is an orally administered pan-RAF inhibitor designed to provide deep and durable suppression of the MAP kinase pathway while potentially limiting treatment resistance.
See Also
- Five stocks we like better than Immuneering
- Dutch Bros Gave Wall Street What It Wanted, So Why Did the Stock Crater?
- Astera Labs Just Crushed Earnings—So Why Are Analysts Cutting Price Targets?
- Sandisk Shares Are Oversold: Bargain or Value Trap?
- IonQ’s Record Revenue Includes a Big SkyWater Boost: Does That Change the Story?
Receive News & Ratings for Immuneering Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Immuneering and related companies with MarketBeat.com's FREE daily email newsletter.
